Got an email about TWSI from Wall Street Newscast:
We recently highlighted APRE as our last pick at $0.015 back on Sept. 11, 2015. Since then APRE has shown steady rise and recently hit a price of $0.11 per share.
This week we are highlighting Tristar Wellness Solutions, Inc. (OTCQB:TWSI) as the next big potential price gainer.
KEY POINTS
Fully Reporting with SEC: First off, unlike a number of other small cap plays TWSI is fully reporting with the SEC, and trades on the OTCQB exchange. This makes it more attractive since they offer fully audited financials and 10Q filings.
FDA Approval: TWSI already has FDA approval for their line of hemostatic blood control products and bandages. You can find many stocks in pre-clinical, Phase 1, Phase 2, and even Phase 3 that trade at much higher market caps, and all without FDA approval. TWSI already has that FDA approval in place, and that alone should have the stock trading at a much higher price.
China Approval and Sales: In additon to having FDA approval in the US, TWSI also received FDA approval in China, or CFDA approval, and had begun sales in China for their products earlier in the summer. These numbers could start showing up in coming quarterly earnings, and makes the stock very undervalued with mere fact they have government approval to sell into China, which many can not do.
NIH Grant for Prostate Cancer Device: In addition, TWSI also received a grant for $1.1 million from the National Institute of Health (NIH) for Phase 2 development of their prostate cancer surgical device. If this was the only project in TWSI the fact they receives a grant, valued at nearly half their current market cap, from the US government, should have sent this stock rocking. This shows TWSI is very much under most of not all radars, and thus not a crowded trade.
Earnings Due Next Week: TWSI is an operational company, and is currently generating sales revenues. For the first six months of 2015 the Company reported total sales revenues of $1.9 million, and is expected to report third quarter sales results sometime in mid-November. This also positions TWSI as a buy as traders can get in before Q3 earnings are released.
Warrants at $1.00: The current CEO of TWSI, Mr. Michael Wax, currently receives no salary, and holds no shares in TWSI, but what he does hold is warrants in the company with a strike price of $1.00 per share. He does not profit unless TWSI gets above $1.00 a share, and that itself could be a bullish signal on where he thinks the stock may be heading.
Potential Acquisition Target: If you research the current CEO background you will see just a few years ago he was successful in developing a medical company, and then having it acquired by NASDAQ listed company. Still in early stages, but this is what could be their goal for TWSI, and that also should provide some attractiness as potential buyout target.
Chart Analysis: You can see from TWSI weekly chart posted above that a break above $0.15 could be a major breakout for stock price, and set the stage for a larger rally. Based on looks of level 2 there are very few shares from its current $0.13 price to $0.30+
Share Structure: TWSI currently has around 28 million shares issued and outstanding, and more importantly a very lite float. The share structure on TWSI has pretty much remained the same for past 12 months, and this shows there is little to no dilution in this stock for any rallies.
If you take all those points mentioned above, TWSI low share structure and float, and fact that Q3 earnings are expected in next week or so, we think TWSI has potential to become a real runner here at just $0.013 per share. www.otcmarkets.com/stock/twsi/quote
About TriStar Wellness Solution, Inc.
TriStar Wellness Solutions, Inc. is a health and wellness company that targets under-met consumer opportunities in the OTC and professional marketplace. Its core strategy plans to meet the growing demand for personalized, care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar recently acquired HemCon Medical Technologies Inc., a developer, manufacturer, and marketer of innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. It also owns the Beauty de MamanTM brand of women's health products.
Contact:
Michael Wax,
CEO
Phone: (503) 245-045 x130
